Document Detail

A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.
MedLine Citation:
PMID:  21977353     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: The primary objective was to evaluate the long-term safety of desvenlafaxine (administered as desvenlafaxine succinate) during open-label treatment in adult outpatients with a primary DSM-IV diagnosis of major depressive disorder (MDD).
METHOD: Depressed adult outpatients (≥ 18 years) who had completed 8-week, double-blind therapy (desvenlafaxine, venlafaxine extended release, or placebo) in a phase 3 study of desvenlafaxine for MDD received up to 10 months of open-label treatment with flexible-dose desvenlafaxine (200 to 400 mg/d). Safety assessments included physical examination, measurement of weight and vital signs, laboratory determinations, and 12-lead electrocardiogram recordings. Adverse events (AEs) and discontinuations due to AEs were monitored throughout the trial. The primary efficacy outcome was mean change from baseline on 17-item Hamilton Depression Rating Scale (HDRS-17) total score. The trial was conducted from August 2003 to March 2006.
RESULTS: The safety population included 1,395 patients who took at least 1 dose of open-label desvenlafaxine. Treatment-emergent AEs were reported by 1,238 of 1,395 patients (89%) during the open-label, on-therapy period. Treatment-emergent AEs reported by 10% or more patients were headache, nausea, hyperhidrosis, dizziness, dry mouth, insomnia, upper respiratory infection, nasopharyngitis, and fatigue. Adverse events were the primary reason for study discontinuation in 296 of 1,395 patients (21%). Ten patients (< 1%) had serious AEs that were considered possibly, probably, or definitely related to the study drug during the on-therapy period. No deaths occurred during the study.
CONCLUSIONS: Desvenlafaxine can be safely administered for up to 12 months. No new safety findings were observed in this study.
TRIAL REGISTRATION: Identifier: NCT01309542.
Karen A Tourian; Bruno Pitrosky; S Krishna Padmanabhan; Gregory R Rosas
Related Documents :
21816353 - Factors affecting placebo acceptability: deception, outcome, and disease severity.
25290953 - Identification of a neurologic scale that optimizes ems detection of older adult trauma...
18597173 - A non-randomized, open study with aripiprazole and ziprasidone for the treatment of agg...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The primary care companion to CNS disorders     Volume:  13     ISSN:  2155-7780     ISO Abbreviation:  Prim Care Companion CNS Disord     Publication Date:  2011  
Date Detail:
Created Date:  2011-10-06     Completed Date:  2011-11-10     Revised Date:  2012-04-27    
Medline Journal Info:
Nlm Unique ID:  101547532     Medline TA:  Prim Care Companion CNS Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  -     Citation Subset:  -    
Wyeth Pharmaceuticals France, Paris (Drs Tourian and Pitrosky); and Pfizer, Collegeville, Pennsylvania (Drs Padmanabhan and Rosas).
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A psychosomatic perspective on takotsubo cardiomyopathy: a case report.
Next Document:  Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional stu...